T2 Biosystems, Inc.
TTOO · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.03 | -0.01 | 0.02 |
| FCF Yield | -17.74% | -12.19% | -77.05% | -30.25% |
| EV / EBITDA | -5.38 | -10.78 | -4.76 | -7.14 |
| Quality | ||||
| ROIC | -139.33% | -71.48% | -106.64% | -43.25% |
| Gross Margin | -106.60% | -37.96% | -103.88% | -57.71% |
| Cash Conversion Ratio | 0.62 | 1.03 | 0.86 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | -31.42% | -36.17% | -36.73% | -36.47% |
| Free Cash Flow Growth | 32.34% | 20.90% | -23.73% | 29.57% |
| Safety | ||||
| Net Debt / EBITDA | -1.74 | -1.78 | -3.52 | -3.71 |
| Interest Coverage | -27.46 | -20.03 | -10.69 | -8.03 |
| Efficiency | ||||
| Inventory Turnover | 1.07 | 0.52 | 0.90 | 0.55 |
| Cash Conversion Cycle | 83.73 | 176.20 | 128.95 | 188.00 |